CAMBRIDGE, Mass., July 29, 2021 (GLOBE NEWSWIRE) — Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage genome editing company focused on developing curative therapeutics using CRISPR/Cas9 technology both in vivo and ex vivo, will present its second quarter 2021 financial results and operational highlights in a conference call on August 5, 2021 at 8 a.m. E.T.
To join the call:
A replay of the call will be available through the Events and Presentations page of the Investors & Media section on Intellia’s website at www.intelliatx.com, beginning on August 5, 2021 at 12 p.m. ET.
About Intellia Therapeutics
Intellia Therapeutics, a leading clinical-stage genome editing company, is developing novel, potentially curative therapeutics using CRISPR/Cas9 technology. To fully realize the transformative potential of CRISPR/Cas9, Intellia is pursuing two primary approaches. The company’s in vivo programs use intravenously administered CRISPR as the therapy, in which proprietary delivery technology enables highly precise editing of disease-causing genes directly within specific target tissues. Intellia’s ex vivo programs use CRISPR to create the therapy by using engineered human cells to treat cancer and autoimmune diseases. Intellia’s deep scientific, technical and clinical development experience, along with its robust intellectual property portfolio, have enabled the company to take a leadership role in harnessing the full potential of CRISPR/Cas9 to create new classes of genetic medicine. Learn more at intelliatx.com. Follow us on Twitter @intelliatweets.
Intellia Contacts:
Investors:
Ian Karp
Senior Vice President, Investor Relations and Corporate Communications
ian.karp@intelliatx.com
Lina Li
Director, Investor Relations
+1-857-706-1612
lina.li@intelliatx.com
Media:
Matt Crenson
Ten Bridge Communications
+1-917-640-7930
media@intelliatx.com
mcrenson@tenbridgecommunications.com
Burlington, Ontario--(Newsfile Corp. - December 8, 2025) - Rapid Dose Therapeutics Corp. (CSE: DOSE) ("RDT" or the…
Eliminates More Than 75% of Prepetition Debt, Positioning Company to Improve Product Affordability and Availability…
Eliminates More Than 75% of Prepetition Debt, Positioning Company to Improve Product Affordability and Availability…
SAN DIEGO--(BUSINESS WIRE)--#ChiroTouch--Claim denials and documentation errors can drain up to 30% of a chiropractic…
WINNIPEG, MB, Dec. 8, 2025 /PRNewswire/ -- Fiberscope is introducing the SOLO PRO+ ExZ1 explosion-proof…
With regulatory shifts, rising clinical costs, and workforce shortages creating mounting challenges to healthcare stability,…